ClinicalTrials.gg
Active, not recruitingNCT07275996MULTI-FRAILUpdated May 4, 2026

Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty

An interventional study of Placebo (Cellulose) and Creatine Monohydrate in Frailty, Sarcopenia and Aging, sponsored by Universidad de Burgos. Active, not recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Universidad de Burgos · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.

Enrollment
69th of 96
50 · median 90
Started
2026
with 20 others
No phase
93 of 132
34 open now
Primary completion
2026-12
later than 31 of 53 live
Registered
104th of 132
by date
Lead sponsor
4 of 132
Universidad de Burgos

Among the 132 studies in Frailty with a site in Spain, this one is the 69th largest by enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2026, is one of 93 with no phase, reaches primary completion later than 31 of the 53 other live ones, and was the 104th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Frailty with a site in Spain, or all of them as a file.
02

Study summary

Sarcopenia and physical frailty are highly prevalent among institutionalized older adults and are major contributors to functional decline, reduced mobility, and loss of independence. Combined exercise and targeted nutritional strategies have emerged as promising approaches to mitigate these age-related impairments.

This randomized, double-blind, placebo-controlled, parallel-group clinical trial aims to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB), administered alongside a supervised multicomponent exercise program, on physical function, body composition, cognitive performance, and quality of life in institutionalized older adults with physical frailty and sarcopenia.

A total of 50 adults aged ≥65 years were enrolled and randomized to one of four intervention groups for 12 weeks: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. A supplement-free follow-up period will be conducted to evaluate the sustainability of intervention effects.

In addition to clinical and functional outcomes, the study incorporates molecular and biological assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to the interventions.

Read the detailed description

This randomized, double-blind, placebo-controlled, parallel-group clinical trial is designed to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB) supplementation when administered alongside a structured multicomponent exercise program in institutionalized older adults with physical frailty and sarcopenia. Sarcopenia and frailty are highly prevalent in this population and are associated with functional disability, increased health care utilization, and reduced quality of life. Nutritional strategies targeting muscle metabolism, when combined with systematic exercise, may attenuate functional decline and improve health outcomes in this vulnerable group.

Study Population and Design

A total of 50 institutionalized adults aged ≥65 years were enrolled from nursing homes in the province of Burgos (Spain). Participants were stratified by sex and randomized to one of four parallel intervention groups for a 12-week intervention period: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. All intervention groups will be followed by a supplement-free follow-up period to assess the persistence of intervention effects.

Intervention

Dietary supplementation will be administered once daily using identical sachets to ensure blinding and equivalent supplement volume across groups. Participants will receive a total of 6 g/day of powder, consisting of cellulose (placebo), creatine monohydrate, HMB, or their combinations, depending on group allocation. Supplement administration will be supervised by nursing staff and mixed with food or beverages according to standard procedures.

All participants will complete a supervised multicomponent exercise program conducted four times per week (\~60 minutes per session). Exercise sessions will include resistance, balance, coordination, and flexibility training, with intensity individually adapted according to functional capacity using the Borg Rating of Perceived Exertion Scale.

Outcomes and Assessments

Clinical, functional, cognitive, and quality-of-life assessments will be conducted at baseline, post-intervention (Week 12), and during follow-up. Primary and secondary outcome measures focus on physical performance, muscle strength, body composition, cognitive function, activities of daily living, nutritional status, and quality of life.

Molecular and Biological Assessments

In addition to clinical outcomes, the study incorporates biological and molecular assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to supplementation and exercise. Venous blood samples will be collected for the analysis of inflammatory markers, oxidative stress and antioxidant status, hormonal profiles, and circulating and exosomal molecular signatures related to muscle metabolism and neuromuscular function. Body composition parameters will be assessed using dual-energy X-ray absorptiometry (DXA).

Statistical Analysis

Statistical analyses will be conducted using mixed-effects models appropriate for parallel-group randomized designs, with treatment group, time, and their interaction as fixed effects, and sex and age included as covariates where appropriate. Post-hoc pairwise comparisons will be adjusted for multiple testing. Statistical significance will be set at p \< 0.05.

Ethics and Data Protection

The study was approved by the Ethics Committee of the University of Burgos (IR 24/2023). Written informed consent was obtained from all participants or their legal representatives. All data will be pseudonymized and managed in accordance with the General Data Protection Regulation (GDPR) and Spanish data protection laws.

03

Conditions studied

  • Frailty
  • Sarcopenia
  • Aging
  • Malnutrition Elderly

Keywords

  • creatine
  • HMB
  • supplementation
  • multicomponent exercise
  • concurrent training
  • institutionalized older adults
  • nursing home
  • physical performance
  • quality of life
  • oxidative stress
  • inflammation
  • geriatric assessment
  • multi-omics
  • microRNA
  • proteomics
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Institutionalized older adults (≥65 years) residing in the Fuentes Blancas Nursing Home (Diputación de Burgos).
  • Clinical diagnosis of frailty or sarcopenia according to validated criteria (e.g., Fried phenotype, SPPB ≤ 9, or low ALMI by DEXA).
  • Ability to participate in an exercise program as assessed by the medical staff.
  • Written provided by the participant or, if cognitively impaired, by a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Severe renal insufficiency ( \< 30 mL/min/1.73m²) or liver failure.
  • Advanced heart failure ( class III-IV) or unstable cardiovascular disease.
  • Active cancer or other severe medical conditions that contraindicate participation.
  • Severe cognitive impairment ( \< 10) precluding adherence to the program without caregiver support.
  • Known allergy or intolerance to creatine, HMB, or inulin.
  • Participation in another clinical trial within the past 3 months.
  • Any condition that, in the opinion of the medical team, may compromise safety or adherence to the intervention.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Creatine + HMB + Exercise

    Participants receive a total of 6 g/day of powder consisting of 3 g/day of creatine monohydrate and 3 g/day of β-hydroxy-β-methylbutyrate (HMB), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.

    Dietary Supplement: Creatine Monohydrate · Behavioral: Multicomponent Exercise Program · Dietary Supplement: β-Hydroxy-β-Methylbutyrate (HMB)

  • Placebo comparator
    Placebo + Exercise

    Participants receive a total of 6 g/day of cellulose (placebo), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.

    Dietary Supplement: Placebo (Cellulose) · Behavioral: Multicomponent Exercise Program

  • Active comparator
    Creatine + Exercise

    Participants receive a total of 6 g/day of powder consisting of 3 g/day of creatine monohydrate and 3 g/day of cellulose (placebo filler), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.

    Dietary Supplement: Placebo (Cellulose) · Dietary Supplement: Creatine Monohydrate · Behavioral: Multicomponent Exercise Program

  • Active comparator
    HMB + Exercise

    Participants receive a total of 6 g/day of powder consisting of 3 g/day of β-hydroxy-β-methylbutyrate (HMB) and 3 g/day of cellulose (placebo filler), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.

    Dietary Supplement: Placebo (Cellulose) · Behavioral: Multicomponent Exercise Program · Dietary Supplement: β-Hydroxy-β-Methylbutyrate (HMB)

Interventions

  • Dietary supplementPlacebo (Cellulose)

    Sachets containing cellulose used as placebo filler to match supplement volume, appearance, and taste. Administered once daily, mixed with yogurt or juice, during the intervention period.

  • Dietary supplementCreatine Monohydrate

    Sachets containing creatine monohydrate used as an active dietary supplement. Administered once daily during the intervention period.

  • BehavioralMulticomponent Exercise Program

    Supervised exercise sessions, 4 times per week (\~60 minutes each), including resistance, endurance, balance, coordination, and flexibility training. Intensity adapted to participants' functional status (Borg scale 6-9). Conducted throughout the 12-week intervention period.

  • Dietary supplementBeta-hydroxyisovaleric acidStudies of Beta-hydroxyisovaleric acidBeta-hydroxyisovaleric acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sachets containing calcium β-hydroxy-β-methylbutyrate used as an active dietary supplement. Administered once daily during the intervention period.

06

What researchers measure

Primary outcomes

  1. Short Physical Performance Battery (SPPB)

    The SPPB assesses lower-extremity physical function through balance, gait speed, and chair stand components, generating a total score ranging from 0 to 12 (higher scores indicate better physical performance). Only the total score will be analyzed as the primary outcome.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  2. Timed Up and Go (TUG)

    Time in seconds to rise from a chair, walk 3 meters, turn around, return, and sit down. Lower times indicate better mobility and balance.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  3. Appendicular Lean Mass (ALM, kg) by DEXA

    Appendicular lean mass (sum of arms and legs lean tissue) measured in kilograms using DEXA. Higher values indicate greater muscle mass in limbs.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

Secondary outcomes

  1. Grip Strength

    Maximal isometric handgrip strength measured in kilograms using a validated hydraulic dynamometer (e.g., Jamar Plus+). Each test performed with the dominant hand in seated position, elbow at 90°. Best of three attempts recorded.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  2. Leg and Back Isometric Strength

    Maximal isometric strength of leg and back extensors assessed in kilograms using a back/leg dynamometer (e.g., Baseline Evaluation Dynamometer). Participants stand on the platform and pull a fixed bar upwards. Best of two attempts recorded.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  3. Seated Arm Curl Test

    Dynamic strength/endurance of upper limbs measured as the number of full arm curl repetitions in 30 seconds using a 2 kg dumbbell for women and a 4 kg dumbbell for men. Participants are seated upright without armrests.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  4. Barthel Index

    Measure of independence in activities of daily living (feeding, bathing, mobility, toileting, etc.). Score ranges from 0 (total dependence) to 100 (independent).

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  5. Mini Nutritional Assessment (MNA)

    Validated tool to screen and assess nutritional status in older adults. Score ranges from 0-30 (higher = better nutritional status).

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  6. Cognitive Function - Mini-Mental State Examination (MMSE)

    Cognitive function assessed using the Mini-Mental State Examination (MMSE). Scores range from 0 to 30, with higher scores indicating better cognition.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  7. Quality of Life - World Health Organization Quality of Life-Brief (WHOQOL-BREF)

    26-item validated questionnaire covering physical, psychological, social and environmental domains. Scores range from 26 to 130; higher scores indicate better perceived quality of life.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  8. Total Lean Mass (kg) by DEXA

    Whole-body lean soft tissue mass measured in kilograms using DEXA (Hologic Discovery or GE Lunar system) with manufacturer's software and standardized positioning. Higher values indicate greater muscle mass.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  9. Total Fat Mass (percent body weight) by DEXA

    Whole-body fat mass measured with DEXA and expressed as a percentage of total body weight. Higher values indicate greater adiposity.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  10. Visceral Adipose Tissue (VAT, cm³) by DEXA

    Visceral adipose tissue (VAT) volume estimated by DEXA in the android region of interest, expressed in cubic centimeters (cm³). Higher values indicate greater central adiposity.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  11. Whole-Body Bone Mineral Density (BMD, g/cm²) by DEXA

    Whole-body BMD measured by DEXA, expressed as grams per square centimeter (g/cm²). Higher values indicate greater bone mineral density.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  12. Cognitive Function - MEC (Spanish Adaptation of MMSE)

    Cognitive function assessed using the MEC (Spanish version of the MMSE). Scores range from 0 to 35, with higher scores indicating better cognition.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  13. Number of Falls

    Incidence of falls recorded by nursing staff during the study period. Unit: number of events per participant. Lower numbers indicate better outcomes.

    Time frame: Baseline to 3-month follow-up

  14. Number of Hospitalizations

    Incidence of hospital admissions for any cause. Unit: number of events per participant. Lower numbers indicate better outcomes.

    Time frame: Baseline to 3-month follow-up

  15. Incidence of Respiratory and Urinary Infections

    Number of documented respiratory and/or urinary tract infections. Unit: number of events per participant. Lower numbers indicate better outcomes.

    Time frame: Baseline to 3-month follow-up

  16. Incidence of Pressure Ulcers

    Number of new pressure ulcers recorded by nursing staff. Lower numbers indicate better outcomes.

    Time frame: Baseline to 3-month follow-up

  17. Incidence of Urinary or Fecal Incontinence

    Occurrence of urinary and/or fecal incontinence episodes recorded in clinical charts. Lower numbers indicate better outcomes.

    Time frame: Baseline to 3-month follow-up

  18. Serum C-reactive protein (CRP, mg/L)

    CRP will be measured in serum samples using a high-sensitivity ELISA. Results expressed in mg/L. Higher values indicate greater systemic inflammation.

    Time frame: Baseline, Week 12 (end of intervention)

  19. Interleukin-6 (IL-6, pg/mL)

    Serum IL-6 concentration will be measured by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.

    Time frame: Baseline, Week 12 (end of intervention)

  20. Tumor Necrosis Factor-alpha (TNF-α, pg/mL)

    Serum TNF-α concentration will be determined by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.

    Time frame: Baseline, Week 12 (end of intervention)

  21. Reduced Glutathione (GSH, µmol/L)

    Plasma reduced glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate better antioxidant status.

    Time frame: Baseline, Week 12 (end of intervention)

  22. Oxidized Glutathione (GSSG, µmol/L)

    Plasma oxidized glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate greater oxidative stress.

    Time frame: Baseline, Week 12 (end of intervention)

  23. Thiobarbituric Acid Reactive Substances (TBARS, nmol MDA equivalents/mL plasma)

    Lipid peroxidation index measured as TBARS and expressed in nmol MDA equivalents/mL of plasma. Higher values indicate greater oxidative stress.

    Time frame: Baseline, Week 12 (end of intervention)

  24. Malondialdehyde (MDA, µmol/L)

    Plasma MDA determined spectrophotometrically and expressed in µmol/L. Higher values indicate greater oxidative stress.

    Time frame: Baseline, Week 12 (end of intervention)

  25. Total Antioxidant Capacity (TAC, mmol Trolox equivalents/L)

    Plasma TAC measured using colorimetric assay and expressed as mmol Trolox equivalents/L. Higher values indicate better antioxidant defense.

    Time frame: Baseline, Week 12 (end of intervention)

  26. Relative expression levels of selected circulating microRNAs

    Changes in the relative expression levels of selected circulating microRNAs associated with muscle metabolism, neuromuscular function, inflammation, oxidative stress, and anabolic signaling pathways. MicroRNAs will be quantified from peripheral blood samples using molecular profiling techniques.

    Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up

  27. Relative expression levels of selected exosome-derived microRNAs

    Changes in the relative expression levels of selected exosome-derived microRNAs related to muscle function, inflammation, and metabolic regulation, analyzed from circulating extracellular vesicles isolated from plasma samples.

    Time frame: Baseline and Week 12

  28. Frequency of selected genetic variants related to creatine and HMB responsiveness

    Analysis of the frequency of selected genetic variants related to muscle metabolism, anabolic signaling, and exercise responsiveness to explore interindividual variability in functional and molecular responses to creatine and HMB supplementation.

    Time frame: Baseline

  29. Relative abundance of selected circulating proteins involved in muscle and inflammatory responses

    Changes in the relative abundance of selected circulating proteins involved in muscle metabolism, inflammation, oxidative stress, and functional adaptation in response to creatine and HMB supplementation combined with exercise. Protein abundance will be assessed using targeted proteomic approaches.

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • Residencia de Mayores Fuentes Blancas (Diputación Provincial de Burgos)
    Burgos, Castille and León 09002, Spain
08

References and documents

Publications

  • Rezola-Pardo C, Rodriguez-Larrad A, Gomez-Diaz J, Lozano-Real G, Mugica-Errazquin I, Patino MJ, Bidaurrazaga-Letona I, Irazusta J, Gil SM. Comparison Between Multicomponent Exercise and Walking Interventions in Long-Term Nursing Homes: A Randomized Controlled Trial. Gerontologist. 2020 Sep 15;60(7):1364-1373. doi: 10.1093/geront/gnz177. PubMed 31845733 ↗
  • Fernandez-Landa J, Calleja-Gonzalez J, Leon-Guereno P, Caballero-Garcia A, Cordova A, Mielgo-Ayuso J. Effect of the Combination of Creatine Monohydrate Plus HMB Supplementation on Sports Performance, Body Composition, Markers of Muscle Damage and Hormone Status: A Systematic Review. Nutrients. 2019 Oct 20;11(10):2528. doi: 10.3390/nu11102528. PubMed 31635165 ↗
  • Fernandez-Landa J, Fernandez-Lazaro D, Calleja-Gonzalez J, Caballero-Garcia A, Cordova A, Leon-Guereno P, Mielgo-Ayuso J. Long-Term Effect of Combination of Creatine Monohydrate Plus beta-Hydroxy beta-Methylbutyrate (HMB) on Exercise-Induced Muscle Damage and Anabolic/Catabolic Hormones in Elite Male Endurance Athletes. Biomolecules. 2020 Jan 15;10(1):140. doi: 10.3390/biom10010140. PubMed 31952174 ↗
  • Fernandez-Landa J, Fernandez-Lazaro D, Calleja-Gonzalez J, Caballero-Garcia A, Cordova Martinez A, Leon-Guereno P, Mielgo-Ayuso J. Effect of Ten Weeks of Creatine Monohydrate Plus HMB Supplementation on Athletic Performance Tests in Elite Male Endurance Athletes. Nutrients. 2020 Jan 10;12(1):193. doi: 10.3390/nu12010193. PubMed 31936727 ↗
  • Holecek M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):529-541. doi: 10.1002/jcsm.12208. Epub 2017 May 10. PubMed 28493406 ↗
  • Cadore EL, Rodriguez-Manas L, Sinclair A, Izquierdo M. Effects of different exercise interventions on risk of falls, gait ability, and balance in physically frail older adults: a systematic review. Rejuvenation Res. 2013 Apr;16(2):105-14. doi: 10.1089/rej.2012.1397. PubMed 23327448 ↗
  • Devries MC, Phillips SM. Creatine supplementation during resistance training in older adults-a meta-analysis. Med Sci Sports Exerc. 2014 Jun;46(6):1194-203. doi: 10.1249/MSS.0000000000000220. PubMed 24576864 ↗
  • Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017 Jan 17;12(1):e0169548. doi: 10.1371/journal.pone.0169548. eCollection 2017. PubMed 28095426 ↗
  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. PubMed 30312372 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results of this trial (including baseline characteristics and outcome measures) will be made available to qualified researchers upon reasonable request. Data will be shared only after publication of the main results and following approval of a research proposal and data access agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning 6 months after publication of the main results, for at least 5 years.

Access criteria: Researchers may request access by contacting the Principal Investigator (Prof. Juan Mielgo-Ayuso, Universidad de Burgos). Requests will be reviewed by the study steering committee. Access will be granted to qualified researchers whose proposals are scientifically and ethically sound, and who agree to sign a data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 9 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Dec 10, 2025
StartActual
Mar 10, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
May 30, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275996
Lead sponsor
Universidad de Burgos
Responsible party
Juan Francisco Mielgo (Full Professor of Physiology, Principal Investigator, Universidad de Burgos) — Principal investigator
First posted
Dec 10, 2025
Start date
Mar 10, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Juan Mielgo-Ayuso, PhD
study chair · Universidad de Burgos

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Creatine monohydrate · Beta-hydroxyisovaleric acid

Start the discussion